AEOL 11207 / Aeolus - LARVOL DELTA

Optimization of lipophilic metalloporphyrins modifies disease outcomes in a rat model of parkinsonism. (PubMed, J Pharmacol Exp Ther) - "In this study, a pharmaceutical formulation of two metalloporphyrin catalytic antioxidants, AEOL11207 and AEOL11114 was tested for oral drug delivery. Both compounds significantly attenuated dopamine depletion, cytokine production, microglia activation, dopaminergic neuronal loss, oxidative/nitrative stress indices and behavioral abnormality in a Parkinson's disease rat model. The results suggest that both metalloporphyrins possess disease-modifying properties which may be useful in treating Parkinson's disease."

Journal • Preclinical • CNS Disorders • Gastrointestinal Disorder • Immunology • Inflammation • Movement Disorders • Parkinson's Disease